RNA Therapeutics
Total Trials
2
As Lead Sponsor
1
As Collaborator
Total Enrollment
105
NCT05814666
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Phase: Phase 2
Role: Lead Sponsor
Start: May 30, 2023
Completion: May 30, 2026
NCT05986240
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Phase: Phase 1
Role: Collaborator
Start: May 8, 2024
Completion: Jul 31, 2028
Loading map...